JP2015511221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511221A5 JP2015511221A5 JP2014553763A JP2014553763A JP2015511221A5 JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5 JP 2014553763 A JP2014553763 A JP 2014553763A JP 2014553763 A JP2014553763 A JP 2014553763A JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxii
- pharmaceutical composition
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592652P | 2012-01-31 | 2012-01-31 | |
| EP12153341.8A EP2623110A1 (en) | 2012-01-31 | 2012-01-31 | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| EP12153341.8 | 2012-01-31 | ||
| US61/592,652 | 2012-01-31 | ||
| PCT/EP2013/051832 WO2013113774A1 (en) | 2012-01-31 | 2013-01-31 | Factor xii inhibitors for the treatment of neurological inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511221A JP2015511221A (ja) | 2015-04-16 |
| JP2015511221A5 true JP2015511221A5 (https=) | 2016-01-14 |
| JP6243854B2 JP6243854B2 (ja) | 2017-12-06 |
Family
ID=45554534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553763A Active JP6243854B2 (ja) | 2012-01-31 | 2013-01-31 | 神経炎症性障害の処置のための第ｘｉｉ因子阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9957329B2 (https=) |
| EP (2) | EP2623110A1 (https=) |
| JP (1) | JP6243854B2 (https=) |
| KR (1) | KR102067394B1 (https=) |
| CN (1) | CN104080470B (https=) |
| AU (1) | AU2013200498B2 (https=) |
| CA (1) | CA2862903C (https=) |
| DK (1) | DK2809336T3 (https=) |
| ES (1) | ES2687018T3 (https=) |
| PL (1) | PL2809336T3 (https=) |
| WO (1) | WO2013113774A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| CN105188750A (zh) | 2013-03-08 | 2015-12-23 | 德国杰特贝林生物制品有限公司 | 治疗和预防远端缺血-再灌注损伤 |
| US10272142B2 (en) * | 2013-11-13 | 2019-04-30 | Shire Viropharma Incorporated | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders |
| JP7109160B2 (ja) | 2014-06-18 | 2022-07-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| KR101744959B1 (ko) | 2014-12-05 | 2017-06-12 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN107405399B (zh) | 2015-01-02 | 2022-02-08 | 武田药品工业株式会社 | 针对血浆激肽释放酶和因子xii的双特异性抗体 |
| WO2016114386A1 (ja) * | 2015-01-15 | 2016-07-21 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患治療剤 |
| AU2016297018B9 (en) | 2015-07-21 | 2022-12-01 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor XIIa |
| RU2757314C2 (ru) | 2016-01-22 | 2021-10-13 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| US11174321B2 (en) | 2016-04-06 | 2021-11-16 | Csl Limited | Method of treating atherosclerosis |
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
| EP3624816A4 (en) * | 2017-05-15 | 2021-02-24 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH STEM CELLS DERIVED FROM ADIPOUS TISSUE |
| AU2018382222B2 (en) * | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| AU2019288299B2 (en) | 2018-06-19 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Anti-factor XII/XIIa antibodies and uses thereof |
| US20240352150A2 (en) * | 2020-06-16 | 2024-10-24 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
| IL325613A (en) | 2023-07-19 | 2026-02-01 | Regeneron Pharma | Antibodies against factor xii/xiia and their uses |
| CN120192392B (zh) * | 2025-05-23 | 2025-09-05 | 昆明医科大学 | 一种版纳绳蚋抗栓肽Sibakazin及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| DE69534265T2 (de) | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| WO2004057343A2 (en) | 2002-12-20 | 2004-07-08 | Axis-Shield Diagnostics Limited | Detection or determination of variants of factor xiia |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PL2298347T3 (pl) | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2591786C (en) * | 2004-12-23 | 2013-07-16 | Bernhard Nieswandt | Prevention of thrombus formation and/or stabilization |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| EP2073898A1 (en) | 2006-10-10 | 2009-07-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement inhibition for improved nerve regeneration |
| CA2678001C (en) * | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses. |
-
2012
- 2012-01-31 EP EP12153341.8A patent/EP2623110A1/en not_active Ceased
-
2013
- 2013-01-31 CN CN201380007416.XA patent/CN104080470B/zh active Active
- 2013-01-31 US US14/374,300 patent/US9957329B2/en active Active
- 2013-01-31 KR KR1020147024214A patent/KR102067394B1/ko active Active
- 2013-01-31 JP JP2014553763A patent/JP6243854B2/ja active Active
- 2013-01-31 WO PCT/EP2013/051832 patent/WO2013113774A1/en not_active Ceased
- 2013-01-31 AU AU2013200498A patent/AU2013200498B2/en active Active
- 2013-01-31 ES ES13701651.5T patent/ES2687018T3/es active Active
- 2013-01-31 DK DK13701651.5T patent/DK2809336T3/en active
- 2013-01-31 CA CA2862903A patent/CA2862903C/en active Active
- 2013-01-31 PL PL13701651T patent/PL2809336T3/pl unknown
- 2013-01-31 EP EP13701651.5A patent/EP2809336B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511221A5 (https=) | ||
| JP6772237B2 (ja) | ブラジキニン媒介障害の評価および治療 | |
| CA2901225C (en) | Treatment and prevention of remote ischemia-reperfusion injury | |
| AU2014301041B2 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
| JP2022023049A (ja) | バイオ医薬組成物 | |
| JP2013517783A5 (https=) | ||
| US20230174666A1 (en) | Anti-cd26 proteins and uses thereof | |
| KR20150107870A (ko) | pKal 매개 장애의 평가, 검정 및 치료 | |
| US7354585B2 (en) | Methods of treating coagulapathic or thrombotic disorders | |
| JP2019506839A5 (https=) | ||
| JP2013542914A5 (https=) | ||
| TW201402607A (zh) | 抗ｂａｆｆ抗ｉｌ－１７雙特異性抗體 | |
| JP2015510875A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| CA2795168A1 (en) | Factor xii inhibitors for treating interstitial lung disease | |
| KR20160089368A (ko) | 자가면역 질환의 진단 및 치료 | |
| CA3184718A1 (en) | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| WO2018039514A1 (en) | Antibody-mediated neutralization of ebolaviruses | |
| JP2017524675A5 (https=) | ||
| CN106029884B (zh) | 新型抗人pai-1抗体 | |
| JP2013539354A5 (https=) | ||
| Bally et al. | Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein | |
| JP7839117B2 (ja) | 抗プロテインｓシングルドメイン抗体及びそれを含むポリペプチド | |
| US20240301073A1 (en) | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | |
| JP2019055949A5 (https=) | ||
| Neves-Ferreira et al. | Natural inhibitors of snake venom metallopeptidases |